Growth and hormone profiling in children with congenital melanocytic naevi
Summary Background Multiple congenital melanocytic naevi (CMN) is a rare mosaic RASopathy, caused by postzygotic activating mutations in NRAS. Growth and hormonal disturbances are described in germline RASopathies, but growth and hormone status have not previously been investigated in individuals wi...
Saved in:
Published in | British journal of dermatology (1951) Vol. 173; no. 6; pp. 1471 - 1478 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.12.2015
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0007-0963 1365-2133 |
DOI | 10.1111/bjd.14091 |
Cover
Summary: | Summary
Background
Multiple congenital melanocytic naevi (CMN) is a rare mosaic RASopathy, caused by postzygotic activating mutations in NRAS. Growth and hormonal disturbances are described in germline RASopathies, but growth and hormone status have not previously been investigated in individuals with CMN.
Objectives
To explore premature thelarche, undescended testes, and a clinically abnormal fat distribution with CMN through prospective endocrinological assessment of a cohort of subjects with CMN, and a retrospective review of longitudinal growth of a larger group of patients with CMN from outpatient clinics (which included all subjects in the endocrinological assessment group).
Patients and methods
Longitudinal growth in a cohort of 202 patients with single or multiple CMN was compared with the U.K. National Child Measurement Programme 2010. Forty‐seven children had hormonal profiling including measurement of circulating luteinizing hormone, follicle‐stimulating hormone, thyroid stimulating hormone, adrenocorticotrophic hormone, growth hormone, prolactin, pro‐opiomelanocortin, estradiol, testosterone, cortisol, thyroxine, insulin‐like growth factor‐1 and leptin; 10 had oral glucose tolerance testing 25 had dual‐energy X‐ray absorptiometry scans for body composition.
Results
Body mass index increased markedly with age (coefficient 0·119, SE 0·016 standard deviation scores per year), at twice the rate of the U.K. population, due to increased adiposity. Three per cent of girls had premature thelarche variant and 6% of boys had persistent undescended testes. Both fat and muscle mass were reduced in areas underlying large naevi, resulting in limb asymmetry and abnormal truncal fat distribution. Anterior pituitary hormone profiling revealed subtle and variable abnormalities. Oral glucose tolerance tests revealed moderate–severe insulin insensitivity in five of 10, and impaired glucose tolerance in one.
Conclusions
Interpersonal variation may reflect the mosaic nature of this disease and patients should be considered individually. Postnatal weight gain is potentially related to the underlying genetic defect; however, environmental reasons cannot be excluded. Naevus‐related reduction of fat and muscle mass suggests local hormonal or metabolic effects on development or growth of adjacent tissues, or mosaic involvement of these tissues at the genetic level. Premature thelarche and undescended testes should be looked for, and investigated, as for any child.
What's already known about this topic?
CMN are caused by postzygotic mutations in the gene NRAS in the majority of cases, classifying it within the group of mosaic RASopathies.
Other germline and mosaic RASopathies are known to have growth and hormonal abnormalities.
No studies have been done on growth or endocrinology in children with CMN.
What does this study add?
Average body mass index increases markedly with age compared with the normal population; this is due to increased adiposity, and can be associated with insulin insensitivity.
Premature thelarche variant and persistent undescended testes are not infrequent findings, but puberty appears to develop normally.
Both fat and muscle mass can be reduced in areas underlying large naevi, resulting in asymmetry.
Linked Comment: Millington, Br J Dermatol 2015; 173: 1366–67. |
---|---|
Bibliography: | Wellcome Trust - No. WT104076MA; No. WT098498 Table S1. Cutaneous phenotype of the congenital melanocytic naevi (CMN) growth cohort (bold) and the endocrine study cohort (not bold), showing that the two cohorts are phenotypically similar. Table S2. Phenotype and absolute values for 10 patients with congenital melanocytic naevi who underwent oral glucose tolerance test. All concentrations other than glucose and insulin were measured only at baseline. ×0, ×30, ×60 and ×90 represent values at time zero, 30, 60 and 90 min, respectively, from ingestion of standard glucose dose. Table S3. Raw data from whole-body composition analysis using DXA scanning of 25 patients with congenital melanocytic naevi. One patient was too young for DXA SDS reference cohort data. SDS, standard deviation score; Wt, weight; Ht, height; DXA, dual-energy X-ray absorptiometry; BMC, bone mineral content; FM, fat mass; FFM, fat-free mass. Fig S1. Upper panel: histograms showing absolute birthweight (kg) in females and males and occipito-frontal head circumference standard deviation score (SDS) for full-term infants in the cohort with congenital melanocytic naevi (CMN). Lower panel: comparison of method of onset of labour and delivery between the CMN cohort and national statistics 2009-10. Numbers for induction of labour do not include elective caesarean section. P-values are for Yate's chi-square test. Gottfried und Julia Bangerter-Rhyner Foundation, Switzerland istex:E6F4779513699294821EEC4E545657AAA90D6C4B ArticleID:BJD14091 Caring Matters Now charity and patient support group University Children's Hospital Zurich Foundation OPO-Foundation, Switzerland ark:/67375/WNG-KRMDQ31J-1 Conflicts of interest Funding sources R.W. was funded by OPO‐Foundation, Switzerland; Gottfried und Julia Bangerter‐Rhyner Foundation, Switzerland; University Children's Hospital Zurich Foundation. V.K. is funded by the Wellcome Trust, grant WT104076MA, and the research was supported by Caring Matters Now charity and patient support group. R.K.S. is funded by the Wellcome Trust, grant WT098498. None declared. |
ISSN: | 0007-0963 1365-2133 |
DOI: | 10.1111/bjd.14091 |